BioWorld MedTech

Sep. 1, 2017

Abbott seeks indication for Amplatzer to treat heart defects in pre-term infants

Abbott Laboratories has initiated a U.S. pivotal clinical study evaluating a modified version of its Amplatzer device designed to correct a common congenital heart defect that occurs in about 80,000 pre-term infants in the U.S. each year. Read More

Researchers behind newly funded Neuros get $2M from NIH for nerve-block studies

Hologic's Brevera biopsy system hits U.S. market

CDSC inks voluntary guidelines for medium-risk CDS systems

New factor helps old iPSCs

Holiday notice

Product briefs

Other news to note

Regulatory front

BioWorld MedTech's Diagnostics Extra

Today's news in brief

BioWorld

BioWorld briefs for April 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 17, 2025.

ADPD 2025: Novel treatment modalities in neurodegenerative disorders

BioWorld Science

The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease...

Many US tariffs paused, pharma warned, EU put on notice

BioWorld

The on-again, off-again U.S. tariffs are off again, at least for now, for more than 75 countries that have reached out to the Trump administration to negotiate...

Ouch! Tariffs hit med tech harder than expected

BioWorld MedTech

First quarter earnings reports from Johnson & Johnson and Abbott Laboratories provided some surprising insights into the likely hit med-tech companies will...